Novel therapeutic strategies for treatment of visceral leishmaniasis
- PMID: 23973338
- DOI: 10.1016/j.drudis.2013.08.005
Novel therapeutic strategies for treatment of visceral leishmaniasis
Abstract
Leishmaniasis reveals itself in two forms, cutaneous and visceral, but the later exerts serious complications and may lead to death, if untreated. The availability of limited number of antileishmanial chemotherapeutic agents, the high cost of treatment, growing incidences of resistance to first line drugs as well as severe toxicities associated with the drugs complicate the treatment of visceral leishmaniasis. To overcome these problems, critical investigation of new therapeutic strategies with potential antileishmanial activity and good tolerability are essential. In this review we explore the different facets of novel therapeutic strategies for treatment of visceral leishmaniasis with a purpose to summarize all the possible treatment tactics, which will help scientists working in this arena to implement their research in a systematic manner.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
[Canine leishmaniasis: evolution of the chemotherapeutic protocols].Parassitologia. 2004 Jun;46(1-2):231-4. Parassitologia. 2004. PMID: 15305724 Review. Italian.
-
Treatment options for visceral leishmaniasis.Expert Rev Anti Infect Ther. 2006 Apr;4(2):187-97. doi: 10.1586/14787210.4.2.187. Expert Rev Anti Infect Ther. 2006. PMID: 16597201 Review.
-
Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan.Drug Dev Ind Pharm. 2010 Nov;36(11):1312-9. doi: 10.3109/03639041003796648. Drug Dev Ind Pharm. 2010. PMID: 20545513 Review.
-
Visceral leishmaniasis in children: a review.Minerva Pediatr. 2010 Aug;62(4):389-95. Minerva Pediatr. 2010. PMID: 20940672 Review.
-
Visceral leishmaniasis: can we dream its eradication?J Assoc Physicians India. 2001 Jun;49:605-8. J Assoc Physicians India. 2001. PMID: 11584933 Review. No abstract available.
Cited by
-
A Targeted and Protease-Activated Genetically Encoded Melittin-Containing Particle for the Treatment of Cutaneous and Visceral Leishmaniasis.ACS Appl Mater Interfaces. 2024 Sep 18;16(37):49148-49163. doi: 10.1021/acsami.4c10426. Epub 2024 Sep 6. ACS Appl Mater Interfaces. 2024. PMID: 39240583 Free PMC article.
-
Innovating Leishmaniasis Treatment: A Critical Chemist's Review of Inorganic Nanomaterials.ACS Infect Dis. 2024 Aug 9;10(8):2485-2506. doi: 10.1021/acsinfecdis.4c00231. Epub 2024 Jul 13. ACS Infect Dis. 2024. PMID: 39001837 Free PMC article. Review.
-
One Platform Comparison of Polymeric and Lipidic Nanoparticles for the Delivery of Amphotericin B.AAPS PharmSciTech. 2023 Nov 10;24(8):226. doi: 10.1208/s12249-023-02672-y. AAPS PharmSciTech. 2023. PMID: 37945925
-
Autophagy in protists and their hosts: When, how and why?Autophagy Rep. 2023;2(1):2149211. doi: 10.1080/27694127.2022.2149211. Epub 2023 Mar 9. Autophagy Rep. 2023. PMID: 37064813 Free PMC article.
-
Current Applications of Plant-Based Drug Delivery Nano Systems for Leishmaniasis Treatment.Pharmaceutics. 2022 Oct 29;14(11):2339. doi: 10.3390/pharmaceutics14112339. Pharmaceutics. 2022. PMID: 36365157 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources